Niastase Rt 1 mg (Eptacog Alfa (Activated) KIT) 1 MG

Niaspase RT 1 mg is a pharmaceutical kit containing Eptacog alfa (activated), used for managing bleeding episodes. This intravenous medication is designed for specific coagulation support.

Strength

1 MG

Manufacturer / TM Owner

NOVO NORDISK CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Niaspase RT 1 mg is primarily used for the treatment and prevention of bleeding episodes in certain medical conditions. Eptacog alfa (activated) works by promoting blood clotting, which can be crucial in managing conditions where clotting is impaired. This medication is often used in scenarios where other treatments may not be effective or suitable.

Side Effects

Common effects of Niaspase RT 1 mg may include localized reactions at the injection site, such as redness or swelling. Some users might experience systemic effects like fever or chills. As with any medication, individual responses can vary, and it's important to monitor for any unusual symptoms.

Precautions & Warnings

Niaspase RT 1 mg should be handled with care, following the instructions provided by a healthcare professional. It is crucial to ensure proper storage and administration to maintain its effectiveness. Users should be aware of any allergies or sensitivities to the components in the kit.

Avoid Interactions

Niaspase RT 1 mg may interact with other medications that affect blood clotting. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain foods may also influence the effectiveness of this medication.

Frequently Asked Questions

Niaspase RT 1 mg is used to manage bleeding episodes in certain medical conditions by promoting blood clotting.

Niaspase RT 1 mg is administered intravenously, typically under the supervision of a healthcare professional.

Common side effects may include localized reactions at the injection site, such as redness or swelling, and systemic effects like fever or chills.

Niaspase RT 1 mg may interact with other medications that affect blood clotting, so it's important to consult a healthcare provider before combining treatments.

Precautions include proper storage, administration, and awareness of any allergies or sensitivities to the components in the kit.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.